Initial Therapeutics Revenue, Growth & Competitor Profile

Company Profile & Annual Report for Initial Therapeutics

Access the complete profile.

Initial Therapeutics Fast Facts

Revenue	$1 - $10 million    See Exact Annual Revenue
Employees	10 - 100Exact Company Size
Primary Industry	5417 Scientific Research & Development Services
Address	285 East Grand Avenue 2200 South San Francisco, CA 94080

Note: Revenues for privately held companies are statistical evaluations.


Initial Therapeutics's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Initial Therapeutics's annual revenues are $1 - $10 million (see exact revenue data)
• What industry is the company in?
  • Initial Therapeutics is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.

Initial Therapeutics Annual Revenue and Growth Rate

Initial Therapeutics	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2025	$1 - $10 million Details in Premium Report
2024
2023
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Initial Therapeutics's revenues are gauged from an analysis of company filings.

Initial Therapeutics's Income Statement (based on Industry Averages)

Initial Therapeutics P&L	$ Millions
Revenue (Sales)
Cost of Goods Sold
Gross Profit
Operating Expenses
Advertising
Salaries and wages
Other Operating Expenses
Total Operating Expenses
Operating Income
EBITDA
EBIT (Earnings Before Interest and Taxes)
Net Profit

Trademark Applications

Trademark applications show the products and services that Initial Therapeutics is developing and marketing. Initial Therapeutics doesn't have any recent trademark applications, indicating Initial Therapeutics is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
INITIAL THERAPEUTICS Pharmaceutical preparations, namely, preparations for the treatment of Parkinson's disease, Huntington's disease and other neuromuscular disorders; medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans for the treatment of Parkinson's disease, Huntington's disease and other neuromuscular disorders	08/10/2020

See all trademarks and details in the Full Report.

Market Share of Initial Therapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Initial Therapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
LEIDOS	Denver, CO	100
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	30
INC RESEARCH	Raleigh, NC	27
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK	Albany, NY	17
FLUOR MARINE PROPULSION	West Mifflin, PA	15
SYNEOS HEALTH	Raleigh, NC	13
ILLUMINA	San Diego, CA	12
UT-BATTELLE	Oak Ridge, TN	11
PRA HOLDINGS	Raleigh, NC	11

Nearby Competitors

These companies are similar in business line and location to Initial Therapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
EMERALD THERAPEUTICS	South San Francisco, CA	100
PHARMACYCLICS	Sunnyvale, CA	59
ALTOS LABS	Redwood City, CA	39
NURO	Mountain View, CA	30
SRI INTERNATIONAL	Menlo Park, CA	27
EXPONENT	Menlo Park, CA	21

Future Competition: Initial Therapeutics's Fastest Growing Competitors

These companies are in the same general field as Initial Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)